celastrol has been researched along with tanshinone ii a in 4 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (tanshinone ii a) | Trials (tanshinone ii a) | Recent Studies (post-2010) (tanshinone ii a) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 61 | 0 | 41 |
| Protein | Taxonomy | celastrol (IC50) | tanshinone ii a (IC50) |
|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | 100 | |
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | 4.82 | |
| Spike glycoprotein | Betacoronavirus England 1 | 0.8 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 0.8 | |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | 11.2 | |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | 11.2 | |
| Telomerase reverse transcriptase | Homo sapiens (human) | 2.75 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.8 | |
| Procathepsin L | Homo sapiens (human) | 0.8 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.14 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 1.2 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.8 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 0.8 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 1.1855 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 8.69 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 2.14 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 0.8 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 2.59 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 6.855 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 6.855 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
4 other study(ies) available for celastrol and tanshinone ii a
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |